Antony A Riley Net Worth And Insider Trading At Forte Biosciences Inc.
Get complete details on Antony A Riley's net worth in the below article. Also, explore the past and latest Riley Antony A insider trading summary here!
The estimated net worth of Antony A Riley is at least $215,854 dollars as of 2023-01-11. Antony A Riley is the CFO of Krystal Biotech Inc and owns about 2,800 shares of Krystal Biotech Inc (KRYS) stock worth over $204,568. Antony A Riley is also the CFO of Forte Biosciences Inc and owns about 11,065 shares of Forte Biosciences Inc (FBRX) stock worth over $11,286. Details can be seen in Antony A Riley's Latest Holdings Summary section.
Antony A Riley Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Antony A Riley owns 2 companies in total, including Forte Biosciences Inc (FBRX) , and Krystal Biotech Inc (KRYS) .
Antony A Riley Latest Holdings Summary
Antony A Riley currently owns a total of 2 stocks. Among these stocks, Antony A Riley owns 2,800 shares of Krystal Biotech Inc (KRYS) as of May 22, 2018, with a value of $204,568 and a weighting of 94.77%. Antony A Riley also owns 11,065 shares of Forte Biosciences Inc (FBRX) as of September 7, 2021, with a value of $11,286 and a weighting of 5.23%.
Antony A Riley Form 4 Trading Tracker
According to the SEC Form 4 filings, Antony A Riley has made a total of 1 transactions in Krystal Biotech Inc (KRYS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Krystal Biotech Inc is the acquisition of 2,800 shares on May 22, 2018, which cost Antony A Riley around $30,100.
According to the SEC Form 4 filings, Antony A Riley has made a total of 2 transactions in Forte Biosciences Inc (FBRX) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Forte Biosciences Inc is the sale of 25,000 shares on September 7, 2021, which brought Antony A Riley around $106,000.
Antony A Riley Owned Company Details
Forte Biosciences Inc(FBRX)
What does Forte Biosciences Inc do?
Forte Biosciences Inc is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial.
Who are the key executives at Forte Biosciences Inc?
Antony A Riley is the Chief Financial Officer of Forte Biosciences Inc. Other key executives at Forte Biosciences Inc include See remarks Hubert C Chen , director & See Remarks Paul A. Wagner , and 10 percent owner Steven Michael Oliveira .
Forte Biosciences Inc (FBRX) Insider Trades Summary
Over the past 18 months, Antony A Riley made 1 insider transaction in Forte Biosciences Inc (FBRX) with a net sale of 25,000. Other recent insider transactions involving Forte Biosciences Inc (FBRX) include a net sale of 900,000 shares made by Paul A. Wagner ,
In summary, during the past 3 months, insiders sold 0 shares of Forte Biosciences Inc (FBRX) in total and bought 100,000 shares, with a net purchase of 100,000 shares. During the past 18 months, 1,025,000 shares of Forte Biosciences Inc (FBRX) were sold and 100,000 shares were bought by its insiders, resulting in a net sale of 925,000 shares.
Krystal Biotech Inc(KRYS)
What does Krystal Biotech Inc do?
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.
Who are the key executives at Krystal Biotech Inc?
Antony A Riley is the Chief Financial Officer of Krystal Biotech Inc. Other key executives at Krystal Biotech Inc include Chief Commercial Officer Andrew C. Orth , director & 10 percent owner & President and CEO Krish S Krishnan , and Chief Accounting Officer Kathryn Romano .
Krystal Biotech Inc (KRYS) Insider Trades Summary
Over the past 18 months, Antony A Riley made no insider transaction in Krystal Biotech Inc (KRYS). Other recent insider transactions involving Krystal Biotech Inc (KRYS) include a net sale of 200,000 shares made by Suma Krishnan , a net sale of 200,000 shares made by Krish S Krishnan , and a net sale of 100,000 shares made by Daniel Janney.
In summary, during the past 3 months, insiders sold 100,000 shares of Krystal Biotech Inc (KRYS) in total and bought 0 shares, with a net sale of 100,000 shares. During the past 18 months, 500,000 shares of Krystal Biotech Inc (KRYS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 500,000 shares.
Spiking Race to 100
We are extremely excited to announce we have a new product called Race to 100. You can track the best investors who have made more than 100% profit in a year and replicate their portfolios in just a few clicks. Be the first to learn these top investors' new trades and trade alongside the shoulders of the giants. Try Race to hundred now at spiking.com/race!
Join the Spiking Wealth Community
Want to learn more about the various trading strategies and see which one suits you the best? Led by Dr. Clemen Chiang, the Spiking Wealth Community is an online community network. Together we are catching the Spikes so that you have faith, hope, and love in everything you do. Spiking Wealth Community helps you to accomplish time squeeze by connecting the dots through online courses, live trading, winning trades, and more. Join us for Free and start your Spiking Wealth Journey today!
*